{"meshTags":["Adult","Aged","Carcinoma, Bronchogenic","Carcinoma, Non-Small-Cell Lung","Carcinoma, Small Cell","Drug Therapy, Combination","Humans","Interferons","Lung Neoplasms","Middle Aged","Thymopentin"],"meshMinor":["Adult","Aged","Carcinoma, Bronchogenic","Carcinoma, Non-Small-Cell Lung","Carcinoma, Small Cell","Drug Therapy, Combination","Humans","Interferons","Lung Neoplasms","Middle Aged","Thymopentin"],"genes":["interferon","thymopentin","interferon","thymopentin"],"publicationTypes":["English Abstract","Journal Article"],"abstract":"The AA. report their experience as to the treatment applied to patients suffering from unremovable bronchial cancers. They can therefore stress the results obtained by chemotherapeutic treatment associated to thymopentin as well as interferon-thymopentin treatment. Elderly patients were subjected to interferon-thymopentin therapy, which helped in improving their life standard and survival.","title":"[Future of immunologic therapy of bronchogenic carcinoma].","pubmedId":"1726851"}